Enanta Pharmaceuticals (ENTA) Other Gross PP&E Adjustments (2016 - 2025)
Enanta Pharmaceuticals (ENTA) has disclosed Other Gross PP&E Adjustments for 14 consecutive years, with -$37.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments fell 330.29% year-over-year to -$37.8 million, compared with a TTM value of -$37.8 million through Dec 2025, down 330.29%, and an annual FY2025 reading of $20.3 million, up 702.26% over the prior year.
- Other Gross PP&E Adjustments was -$37.8 million for Q4 2025 at Enanta Pharmaceuticals, down from $20.3 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $20.3 million in Q3 2025 and bottomed at -$37.8 million in Q4 2025.
- Average Other Gross PP&E Adjustments over 5 years is -$8.4 million, with a median of -$9.1 million recorded in 2021.
- Peak annual rise in Other Gross PP&E Adjustments hit 702.26% in 2025, while the deepest fall reached 330.29% in 2025.
- Year by year, Other Gross PP&E Adjustments stood at -$19.4 million in 2021, then decreased by 21.32% to -$23.5 million in 2022, then grew by 9.33% to -$21.3 million in 2023, then surged by 176.98% to $16.4 million in 2024, then crashed by 330.29% to -$37.8 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for ENTA at -$37.8 million in Q4 2025, $20.3 million in Q3 2025, and $19.6 million in Q2 2025.